Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New EudraVigilance System To Usher In Simplified Reporting of ADRs From Nov. 22

Executive Summary

The European Medicines Agency is asking drug companies and EU national competent authorities to prepare for the late November launch of the new EU pharmacovigilance database, which will have enhanced functionalities for reporting and analysing suspected adverse reactions.

You may also be interested in...

More Than 1.2m Adverse Drug Reactions Reported In EU In 2016; EMA Reviewed 2,000 Safety Signals

The European Medicines Agency has published details of the drug safety issues it dealt with in 2016, noting that more than 1.2 million adverse drug reaction reports were received and that it reviewed in excess of 2,000 potential safety signals. A total of 118 products were withdrawn from European markets.

EMA Rolls Out Monthly Time Slots To Stagger Registration To Revamped EudraVigilance Database

The European Medicines Agency has drawn up a list of approximately 3,000 marketing authorization holders that need to be registered to the modernized pharmacovigilance database by November. The agency will tackle the list in alphabetical order, undertaking around 600 registrations per month starting June 1. Companies that fail to apply within the designated monthly slot will be put at the end of the queue, which may delay their access to the database.

Modernized Pharmacovigilance Database Nears In Switzerland

Switzerland is on track with plans to adopt a new modernized pharmacovigilance system with enhanced data analysis capabilities. The new system will not result in any changes to how companies and healthcare professionals report adverse drug reactions to Swissmedic.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts